NEORx VERLUMA IMAGING AGENT FOR INITIAL STAGING OF SMALL CELL LUNG CANCER ACCURATE IN 82% OF PATIENTS; GAINS RECOMMENDATION FROM FDA COMMITTEE.
Executive Summary
NeoRx' monoclonal antibody imaging agent Verluma (technetium 99m nofetumomab merpentan) accurately staged 73 of 89 small cell lung cancer patients with a positive biopsy (82%) compared to 80 of 89 (90%) with the standard battery of tests, leading FDA's Oncologic Drugs Advisory Committee to recommend the diagnostic for approval for initial staging of SCLC in a 9-4 vote Dec. 14.